STOCK TITAN

Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 A.M. Pacific Time (1:30 P.M. Eastern Time). Interested parties can access the live webcast on Teva's Investor Relations website, with an archived version available within 24 hours and accessible for up to 30 days. Teva has over 3,500 products in its portfolio, serving around 200 million patients globally every day.

Positive
  • None.
Negative
  • None.

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023. The presentation will begin at 10:30 A.M. Pacific Time (1:30 P.M. Eastern Time).

To access a live webcast of the presentation, visit Teva’s Investor Relations website at http://ir.tevapharm.com/.

An archived version of the webcast will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This document and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our substantial indebtedness; our business and operations in general including: uncertainty regarding the COVID-19 pandemic and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Rerport on Form 10-Q for the third quarter of 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

IR Contacts

Ran Meir

(267) 468-4475

Yael Ashman

+972 (3) 914 8262

PR Contacts

Kelley Dougherty

(973) 832-2810

Eden Klein

+972 (3) 906 2645

Source: Teva Pharmaceutical Industries Limited

FAQ

When will Teva present at the J.P. Morgan Healthcare Conference?

Teva will present on January 11, 2023, at 10:30 A.M. Pacific Time.

How can I access the webcast of Teva's presentation?

The live webcast can be accessed on Teva’s Investor Relations website.

How long will the archived webcast of Teva's presentation be available?

The archived webcast will be available for up to 30 days after the live discussion.

What is Teva's product portfolio size?

Teva has a portfolio of over 3,500 products.

How many people use Teva medications daily?

Around 200 million people take a Teva medicine every day.

Teva Pharmaceutical Industries Limited American Depositary Shares

NYSE:TEVA

TEVA Rankings

TEVA Latest News

TEVA Stock Data

19.22B
1.13B
0%
57.25%
1.6%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
TEL AVIV